• Clearmind Medicine will execute a 1-for-10 reverse share split effective May 21, 2026.
• The move targets renewed compliance with Nasdaq’s minimum bid price requirement.
• Issued and outstanding common shares are expected to drop to about 1,019,033 from 10,190,337, with fractional shares rounded up to whole shares.
• Outstanding options and warrants will be adjusted proportionately for share count and exercise price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190600PRIMZONEFULLFEED9722873) on May 19, 2026, and is solely responsible for the information contained therein.